Cytel Offers On-Demand Access to Webinar on Synethic, External Control Arms
A new on-demand webinar from Cytel offers insights into synthetic and external control arms in clinical trials. The webinar features [...]
Kreis: Challenging Price of Costly CF Drug Not ‘Discrimination’
Maurice Kreis, head of the New Hampshire Office of the Consumer Advocate, says challenging the price of Vertex Pharmaceuticals' cystic [...]
ICER to Review Most Significant Drug Price Hikes
The Institute for Clinical and Economic Review (ICER) is set to review whether the most significant drug price increases are [...]
Analysis Finds Clinical Trial Costs are Actually Modest
A new analysis published in BMJ Open suggests that clinical trial costs for new drugs are generally modest, according to [...]
New Definition of HTA
In a letter to the editor published in Value in Health, Brian O'Rourke, Wija Oortwijn and Tara Schuller offer a [...]
Report: EMA Considers Big Data Network ‘Priority’
The European Medicines Agency (EMA) says the development of a big data network is a "priority" project, according to a [...]
ISPOR Europe 2020 Deadline for Abstract Submissions Nears
The abstract submission deadline for ISPOR's upcoming European meeting is July 8. ISPOR 2020 Europe is set to kick off [...]
Researchers Support Targeted Population Health Interventions to Boost COVID-19 Outcomes
Health care systems should target population health interventions to patients with existing chronic diseases to bolster COVID-19 outcomes, researchers in [...]
Where Epidemiologists are Leaning on Kids Returning to School
A recent New York Times Upshot article offers comments from 133 epidemiologists on the matter of children returning to school [...]
Article: U.S. Should Scrap Specialty Drug Label
The U.S. should abandon the specialty-drug label for high-cost drugs and follow suit with other countries that categorize drugs by [...]
ICER to CF Community: ‘We Support Actions to Receive Fair Prices’
The Institute for Clinical and Economic Review (ICER) in a letter to the cystic fibrosis community says it supports fair [...]
How Can Pharma Best Interact with ICER?
A new report from FirstWord looks at how pharma can best engage with the Institute for Clinical and Economic Review [...]
Using AI, NLP and Data Visualization with RWE to Generate Insights into Care Gaps: Retrospective Cohort Analysis of Fracture Risk in Patients with Osteopenia and Osteoporosis
Sponsored by Veradigm Real world data (RWD) are being used by an increasingly diverse group of stakeholders. As an example, [...]
Report Suggests COVID-19 Could Cost Insurers up to $547 Billion
A new report from Wakely, commissioned by America's Health Insurance Plans (AHIP), suggests COVID-19 could cost payers between $30 [...]
Optum: 8 Forces That Will Determine the Future
Optum in a recent perspective offers eight main drivers that will determine the course of health care beyond the COVID-19 [...]
Houghton St Press Launches New Journal
Houghton St Press recently launched its 10th journal, The Journal of Health Policy and Economics (JOHPEC). The new peer-reviewed journal [...]
Health Affairs Editor: Institutions Must Use Power to Fight Racism
Health Affairs Editor Alan Weil in a recent blog post says health care institutions must "use their power to fight [...]
NPC Blog Post Reflects on AMCP’s Format
The National Pharmaceutical Council (NPC) in a recent blog post reflects on the Academy of Managed Care Pharmacy's (AMCP) Format [...]
Study Finds ‘Extensive’ Financial Relationships Between Medical Associations, Industry
A recent study published in The BMJ suggests there exist "extensive" financial ties between influential medical associations and pharmaceutical and [...]
Inovalon Launches New Infection Surveillance, Reporting Solution
Inovalon has launched a new infection surveillance and reporting solution to help health care facilities in real-time map infections demonstrating [...]
Virtual Series to Offer Insight into What’s in Store for Payers
An upcoming FierceHealthcare online virtual series will look at what payers can expect in the year ahead and beyond. "FierceHealthPayer [...]
COTA’s Narayanan Talks RWD in Interview with Aetion
COTA Healthcare's Life Sciences Vice President Viraj Narayanan in a recent interview with Aetion discussed how oncological real-world data can [...]
Shafrin: VBAs ‘Will Never Make Up a Majority of Reimbursement’
Healthcare economist Jason Shafrin says that while value-based agreements can be useful in a number of situations, they won't have [...]
Article Examines Coverage of Biosimilars
A recent article published in JAMA examines how commercial health plans cover biosimilars compared to their reference products. While Congress [...]
Study: No Confirmed Benefit of Hydroxychloroquine or Chloroquine in Treatment of COVID-19
Researchers in a recent study were unable to confirm any benefits of hydroxychloroquine or chloroquine in the treatment of COVID-19. [...]